Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans.
Saved in:
| Title: | Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans. |
|---|---|
| Authors: | Nussbaum JC; Merck & Co., Inc., Kenilworth, New Jersey, USA., Hussain A; Merck & Co., Inc., Kenilworth, New Jersey, USA., Ma B; Merck & Co., Inc., Kenilworth, New Jersey, USA., Min KC; Merck & Co., Inc., Kenilworth, New Jersey, USA., Chen Q; Merck & Co., Inc., Kenilworth, New Jersey, USA., Tomek C; Celerion Inc., Lincoln, Nebraska, USA., Iwamoto M; Merck & Co., Inc., Kenilworth, New Jersey, USA., Stoch SA; Merck & Co., Inc., Kenilworth, New Jersey, USA. |
| Source: | Pharmacology research & perspectives [Pharmacol Res Perspect] 2022 Feb; Vol. 10 (1), pp. e00924. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
